LG Chem announced on the 1st that it has applied for a phase 3 clinical trial plan for Tigulixostat, a new gout drug developed by the U.S. Food and Drug Administration (FDA).

This is the first time that LG Chem has started phase 3 clinical trials of new drugs in global regions such as the U.S. The company's strategy is to significantly expand its bio business area centered on domestic demand and emerging markets to the U.S. and Europe.

This clinical trial evaluates safety and effectiveness compared to placebo in 350 adult gout patients with hyperuricemia in multiple countries, including the United States, at the point of six months of taking Tigulixostat. The primary evaluation index was